Gılaburu

The EMA herbal monograph register does not include a Viburnum opulus entry — not traditional-use, not well-established-use. Cramp Bark (the dried bark of V. opulus / V. prunifolium) appears in the British Herbal Pharmacopoeia (BHP) and the American Herbal Pharmacopoeia (AHP), neither of which is EU-binding. The European Pharmacopoeia does not carry a V. opulus monograph at the time of writing. Marketing copy that claims 'EMA-approved' status for V. opulus — typically for kidney-stone or cardiovascular indications — is overstating the regulatory record. Preliminary work exists (PMC7595025 small Turkish clinical study on distal ureteral stones; PMC4137613 rat-model calcium oxalate study) but neither equates to an EMA-authorised therapeutic claim.

The Kajszczak et al. Nutrients 2020 review is the flagship peer-reviewed phytochemistry reference: phenolic compounds + vitamin C 12.4–164.0 mg/100g FW (most cultivars in the 28–43 mg/100g medium-level band), anthocyanins 24.3–51.3 mg cyanidin-3-glucoside equivalents per 100g juice, iridoids and essential oils present, sensory profile bitter + astringent + sour, juice pH 2.6–3.7, Brix 7.5–11.6%. The 'Krasnaya Grozd' cultivar used in eastern European trials reaches 1,168 mg/100g total phenolics. The 'post-frost chemistry transformation' framing common in gardening literature is extrapolated from V. trilobum (American cranberrybush) work — peer-reviewed pre-frost-to-post-frost compositional change on V. opulus specifically is not documented.

The 2023 ScienceDirect safety assessment of V. opulus juice and the PMC8182012 acute and subacute oral toxicity study on Sprague-Dawley rats place the acute oral LD50 above 2,000 mg/kg (standard non-toxic threshold). The 28-day subacute study at 2,000 mg/kg/day produced documented kidney + liver + adipose-tissue toxicity markers and elevated platelet counts; 500 mg/kg/day was the documented safe level. The 4× ratio between safe and adverse-effect doses is a relatively narrow therapeutic window for a botanical — traditional juice doses sit well inside, but supplement-grade concentrated extract positioning should disclose this margin.

Traditional preparations (whole fruit, dried berry, juice concentrate) have documented food consumption history in Slavic Europe (kalyna, sok kalina) and inner Anatolia (gılaburu) predating May 1997, which is the conventional cutoff for 'history of consumption' exclusion from Novel Food review. The pragmatic procurement framing is that traditional V. opulus berry preparations likely fall outside Novel Food scope, but novel extracts — supercritical CO₂ concentrates, isolated iridoid fractions, standardised polyphenol preparations — may trigger Novel Food review depending on the preparation route. Confirm the EC Novel Food catalogue entry for the exact preparation form before commercial commitment.

Documented commercial supply runs in three distinct postures. Ukrainian wildcraft (Carpathian Bukovina cross-border zone, Pieroni et al. ethnobotanical literature) is the active dried-berry export flow. Romanian Carpathian wild collection sits in the same ethnobotanical territory without consolidated commercial volume data in public trade aggregators — Tandor's Suceava base is geographically inside this Bukovina region. Turkish cultivated production (Kayseri Akkışla + Bünyan, ~65% concentrated in Akkışla per ORAN 2018) carries GI registration and runs primarily into the juice concentrate channel. The 2021 Turkish harvest reported ~50% yield loss (Tridge), so single-origin Turkish-only allocation should be cross-checked against current-year crop conditions before commitment.